Daiichi Sankyo signs agreement with Lead Discovery Centre
Daiichi Sankyo, Max Planck Innovation and the Lead Discovery Centre have signed an agreement providing Daiichi Sankyo with the option to receive the exclusive rights to a new lead compound for the treatment of cancer to be discovered and developed at the Lead Discovery Centre.
This new partnership builds on biology insights in the field of transcriptional regulation from the work of Prof.
Matthias Geyer at the Max Planck Institute of Molecular Physiology in Dortmund and the Research Centre caesar (Centre of Advanced European Studies and Research) in Bonn, Germany. Combined with the Lead Discovery Centre’s strong drug discovery expertise in the design of highly selective kinase inhibitors, Daiichi Sankyo,
Max Planck researchers and the Lead Discovery Centre will now closely cooperate to further optimize these novel compounds that target cancer cell transcription and proliferation. Daiichi Sankyo together with the Max Planck Society, supported by Max Planck Foundation, will jointly fund the respective drug discovery efforts at the Lead Discovery Centre.
The agreement includes an upfront payment as well as development and sales milestones plus royalties. The licensing revenues will be shared between Max Planck Society, the Lead Discovery Centre and all contributing researchers and institutions.